iotrolan has been researched along with Myelopathy in 2 studies
iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palmers, Y | 1 |
| Kuhn, FP | 1 |
| Petersen, D | 1 |
| De Greef, D | 1 |
| Carella, A | 1 |
| D'Aprile, P | 1 |
| Medicamento, N | 1 |
| Simone, F | 1 |
| Paglialonga, P | 1 |
1 trial available for iotrolan and Myelopathy
| Article | Year |
|---|---|
Comparison in myelography between iodixanol 270 and 320 mgI/ml and iotrolan 300 mgI/ml: a multicentre, randomised, parallel-group, double-blind, phase III trial.
Topics: Contrast Media; Double-Blind Method; Female; Headache; Humans; Iodine; Male; Middle Aged; Myelograph | 2002 |
1 other study available for iotrolan and Myelopathy
| Article | Year |
|---|---|
Iotrol: a new contrast medium for the subarachnoid space. Our clinical experience in myelography.
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Humans; Iodobenzoates; Male; Middle Aged; Myelograp | 1988 |